These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33275745)

  • 1. Outpatient transfusions for myelodysplastic syndromes.
    Wood EM; McQuilten ZK
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):167-174. PubMed ID: 33275745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial.
    Stanworth SJ; Killick S; McQuilten ZK; Karakantza M; Weinkove R; Smethurst H; Pankhurst LA; Hodge RL; Hopkins V; Thomas HL; Deary AJ; Callum J; Lin Y; Wood EM; Buckstein R; Bowen D;
    Br J Haematol; 2020 Apr; 189(2):279-290. PubMed ID: 31960409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC-ENHANCE.
    Buckstein R; Callum J; Prica A; Bowen D; Wells RA; Leber B; Heddle N; Chodirker L; Cheung M; Mozessohn L; Yee K; Gallagher J; Parmentier A; Jamula E; Zhang L; Mamedov A; Stanworth SJ; Lin Y
    Transfusion; 2024 Feb; 64(2):223-235. PubMed ID: 38323704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes.
    Abel GA; Klepin HD; Magnavita ES; Jaung T; Lu W; Shallis RM; Hantel A; Bahl NE; Dellinger-Johnson R; Winer ES; Zeidan AM
    Transfusion; 2021 Oct; 61(10):2830-2836. PubMed ID: 34251040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review.
    Pinchon DJ; Stanworth SJ; Dorée C; Brunskill S; Norfolk DR
    Am J Hematol; 2009 Oct; 84(10):671-7. PubMed ID: 19705430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfusion Support of Patients with Myelodysplastic Syndromes.
    Guarente J; Tormey C
    Clin Lab Med; 2023 Dec; 43(4):669-683. PubMed ID: 37865510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes.
    Ryblom H; Hast R; Hellström-Lindberg E; Winterling J; Johansson E
    Eur J Oncol Nurs; 2015 Apr; 19(2):99-106. PubMed ID: 25488465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes.
    Cheok KPL; Chhetri R; Wee LYA; Friel O; Pham A; Salvi A; McRae S; Bardy P; Singhal D; Roxby DJ; Wood EM; Hiwase DK
    Transfusion; 2020 Oct; 60(10):2192-2198. PubMed ID: 32905635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restrictive Versus Liberal Transfusion Strategies in Myelodysplastic Syndrome and Beyond.
    Wilde L; Pan J
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):758-762. PubMed ID: 31678078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.
    Balducci L
    Cancer; 2006 May; 106(10):2087-94. PubMed ID: 16607649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes.
    King D; Schmidt R; Lesser M; Houk A; Salkeld E; Cogle CR
    Leuk Res; 2020 Sep; 96():106425. PubMed ID: 32702549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim.
    Krečak I; Skorić I; Čengić M; Krečak F; Skelin M
    Transfus Apher Sci; 2023 Apr; 62(2):103582. PubMed ID: 36253251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red blood cell transfusion in myelodysplastic syndromes: A systematic review.
    Kaka S; Jahangirnia A; Beauregard N; Davis A; Tinmouth A; Chin-Yee N
    Transfus Med; 2022 Feb; 32(1):3-23. PubMed ID: 34927286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicians' experience in blood supply shortages and the top factors that impact the clinical, economic, and humanistic outcomes of patients with myelodysplastic syndromes in 5 European countries.
    Gupta S; Kulasekararaj AG; Costantino H; Grisolano J; Tang J; Jones S; Tang D
    Curr Med Res Opin; 2023 Feb; 39(2):239-247. PubMed ID: 36453466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.
    Vijenthira A; Premkumar D; Callum J; Lin Y; Wells RA; Chodirker L; Lenis M; Mamedov A; Buckstein R
    Leuk Res; 2019 Jan; 76():76-81. PubMed ID: 30580105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications.
    Gupta P; LeRoy SC; Luikart SD; Bateman A; Morrison VA
    Leuk Res; 1999 Oct; 23(10):953-9. PubMed ID: 10573142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
    Jabbour E; Kantarjian HM; Koller C; Taher A
    Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes.
    Mo A; Wood E; Shortt J; Charlton A; Evers D; Hoeks M; Pritchard E; Daly J; Hodgson C; Opat S; Bowen D; Reynolds J; Thi Phung Thao L; Stanworth SJ; McQuilten Z
    Transfusion; 2024 Feb; 64(2):236-247. PubMed ID: 38214417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.